Junshi Bio's Toripalimab for the Treatment of Small Cell Lung Cancer Receives Orphan Drug Designation by the U.S. FDA

Orphan drugs, also known as rare disease drugs, refer to drugs used for the prevention, treatment and diagnosis of rare diseases

^{Lung cancer is currently the second most common malignant tumor in the world in terms of} morbidity and mortality1

Currently, Junshi Biosciences is conducting a registrational clinical study for small cell lung cancer, the JUPITER-08 study (NCT04012606), and has completed the enrollment of subjects

"Currently, there are significant differences

Toripalimab was independently developed by Junshi Bio and has completely independent intellectual property rights worldwide.

references

1. Cao Maomao, Chen Wanqing.
   
   

   Toripalimab injection (Tuoyi® ⁾ , as the first domestically produced monoclonal antibody targeting PD-1 approved for marketing in China, has been supported by major national science and technology special projects and won the highest award in the national patent field "China Patent Gold Award"

   
   

   In March 2021, toripalimab was included in the Breakthrough Therapy Drug Program by the NMPA for the first-line treatment of advanced mucosal melanoma

   
   

   Toripalimab started clinical research and development in early 2016.

   
   

   About Junshi Bio

   Junshi Bio (688180.

   
   

   Relying on the core platform technology of protein engineering, Junshi Bio is at the forefront of international macromolecular drug research and development, and has obtained the first domestic anti-PD-1 monoclonal antibody NMPA marketing approval, domestic anti-PCSK9 monoclonal antibody NMPA clinical application approval, and the world's first anti-tumor anti-cancer drug.

   
   

   Since the outbreak of the epidemic in 2020, Junshi has responded quickly, joined hands with domestic and foreign scientific research institutions and enterprises to fight the epidemic, and used technology accumulation to rapidly develop a variety of innovative drugs for the treatment of COVID-19, actively undertaking the social responsibility of Chinese pharmaceutical companies

   
   

   At present, Junshi Bio has more than 2,800 employees worldwide, located in San Francisco and Maryland in the United States, and Shanghai, Suzhou, Beijing and Guangzhou in China

   
   

   Official website:WeChat: Junshi Bio